212 related articles for article (PubMed ID: 9635848)
21. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
23. Long-term nephrotoxicity in adult survivors of childhood cancer.
Dekkers IA; Blijdorp K; Cransberg K; Pluijm SM; Pieters R; Neggers SJ; van den Heuvel-Eibrink MM
Clin J Am Soc Nephrol; 2013 Jun; 8(6):922-9. PubMed ID: 23411430
[TBL] [Abstract][Full Text] [Related]
24. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
Jones DP; Chesney RW
Curr Opin Pediatr; 1995 Apr; 7(2):208-13. PubMed ID: 7787938
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum.
Rossi R; Danzebrink S; Hillebrand D; Linnenbürger K; Ullrich K; Jürgens H
Med Pediatr Oncol; 1994; 22(1):27-32. PubMed ID: 8232077
[TBL] [Abstract][Full Text] [Related]
26. Lower Blood Pressure-Induced Renal Hypoperfusion Promotes Cisplatin-Induced Nephrotoxicity.
Mizuno T; Hayashi T; Shimabukuro Y; Murase M; Hayashi H; Ishikawa K; Takahashi K; Yuzawa Y; Yamada S; Nagamatsu T
Oncology; 2016; 90(6):313-20. PubMed ID: 27225867
[TBL] [Abstract][Full Text] [Related]
27. Strategies to prevent nephrotoxicity of anticancer drugs.
Skinner R
Curr Opin Oncol; 1995 Jul; 7(4):310-5. PubMed ID: 7578377
[TBL] [Abstract][Full Text] [Related]
28. Nephrotoxicity after ifosfamide.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
[TBL] [Abstract][Full Text] [Related]
29. Cumulative renal tubular damage associated with cisplatin nephrotoxicity.
Goren MP; Wright RK; Horowitz ME
Cancer Chemother Pharmacol; 1986; 18(1):69-73. PubMed ID: 2875808
[TBL] [Abstract][Full Text] [Related]
30. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
31. Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
Rossi RM; Kist C; Wurster U; Külpmann WR; Ehrich JH
Pediatr Nephrol; 1994 Apr; 8(2):151-6. PubMed ID: 8018491
[TBL] [Abstract][Full Text] [Related]
32. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Skinner R
Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
[TBL] [Abstract][Full Text] [Related]
33. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
[TBL] [Abstract][Full Text] [Related]
34. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
Caglar K; Kinalp C; Arpaci F; Turan M; Saglam K; Ozturk B; Komurcu S; Yavuz I; Yenicesu M; Ozet A; Vural A
Nephrol Dial Transplant; 2002 Nov; 17(11):1931-5. PubMed ID: 12401849
[TBL] [Abstract][Full Text] [Related]
35. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.
Sánchez-González PD; López-Hernández FJ; López-Novoa JM; Morales AI
Crit Rev Toxicol; 2011 Nov; 41(10):803-21. PubMed ID: 21838551
[TBL] [Abstract][Full Text] [Related]
36. Renal toxicity and chemotherapy in children with cancer.
Ruggiero A; Ferrara P; Attinà G; Rizzo D; Riccardi R
Br J Clin Pharmacol; 2017 Dec; 83(12):2605-2614. PubMed ID: 28758697
[TBL] [Abstract][Full Text] [Related]
37. Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial.
Patzer L; Ringelmann F; Kentouche K; Fuchs D; Zintl F; Brandis M; Zimmerhackl LB; Misselwitz J
Bone Marrow Transplant; 2001 Feb; 27(3):319-27. PubMed ID: 11277181
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer.
Karademir LD; Dogruel F; Kocyigit I; Yazici C; Unal A; Sipahioglu MH; Oymak O; Tokgoz B
Ren Fail; 2016 Jun; 38(5):806-14. PubMed ID: 27049176
[TBL] [Abstract][Full Text] [Related]
39. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
40. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
